A Study of BL-B01D1+TKI±Pembrolizumab in Patients With Locally Advanced or Metastatic Renal Cancer
Clinical trial NCT06962787 · RECRUITING
Trial details
- NCT number
- NCT06962787
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2025-07-28
- Primary completion
- 2027-05-01
- Enrollment
- 260
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.